Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20818609 | 0.86 | MTNR1A (0.33) | MAPTMTNR1AMTNR1B | |
| SCHEMBL15042268 | 0.84 | MAPT (0.52) | MAPTTSHRMTNR1AMTNR1B | |
| SCHEMBL24452488 | 0.77 | MAPT (0.37) | MAPTTSHR | |
| SCHEMBL21217064 | 0.75 | MAPT (0.48) | MAPTTSHRMTNR1AMTNR1B | |
| SCHEMBL21210733 | 0.75 | MAPT (0.48) | MAPTTSHRMTNR1AMTNR1B | |
| SCHEMBL12596728 | 0.74 | — | — | |
| SCHEMBL24259167 | 0.73 | MAPT (0.47) | MAPTTSHRMTNR1AMTNR1B | |
| SCHEMBL23758352 | 0.72 | MAPT (0.41) | MAPTMTNR1AMTNR1B | |
| SCHEMBL20818669 | 0.72 | MAPT (0.41) | MAPTMTNR1AMTNR1B | |
| SCHEMBL24258932 | 0.71 | FAAH (0.35) | TSHRHIF1AFAAHTRPV1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | MAPT 398/4885TSHR 798/4885HIF1A 4498/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | MAPT 398/4885TSHR 798/4885HIF1A 4498/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | MAPT 398/4885TSHR 798/4885HIF1A 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.